IFNA1 and hepatocellular carcinoma: As a recombinant protein, IFN-α is one of a few approved angiogenesis inhibitors, and it has been applied in the clinical treatment of HCC [14-16], renal cancer [17], prostate cancer [18], malignant melanoma [19-22], chronic myelogenous leukemia [23-25], and superficial bladder carcinoma [26].